Achilles Therapeutics: Funding, Investors & Team (Sep 2026)
Achilles Therapeutics is a designer of immunotherapies planned to propose future, patient-explicit treatments to treat malignant growth. The organization's immunotherapies saddle the invulnerable framework to obliterate disease cells that target truncal growth neo-antigens and banners to the resistant framework present on the outer layer of each and every malignant growth cell, empowering researchers to target and annihilate cancers without hurting sound tissues.
Achilles Therapeutics has raised $5.1M across 2 funding rounds on record, the most recent a Grant of $4.1M announced in Jul 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Achilles Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2022.
Achilles Therapeutics Funding Rounds
Achilles Therapeutics raised $1.0M in an undisclosed round announced in May 2021.
1.2 years later, a Grant of $4.1M was announced in Jul 2022.
Achilles Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Achilles Therapeutics Funding Compared to Other Biotechnology Startups
Achilles Therapeutics' latest round of $4.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Achilles Therapeutics in Biotechnology and London
Companies Similar to Achilles Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Achilles Therapeutics Funding FAQs
What does Achilles Therapeutics do?
Achilles Therapeutics is a designer of immunotherapies planned to propose future, patient-explicit treatments to treat malignant growth. The organization's immunotherapies saddle the invulnerable framework to obliterate disease cells that target truncal growth neo-antigens and banners to the resistant framework present on the outer layer of each and every malignant growth cell, empowering researchers to target and annihilate cancers without hurting sound tissues.
How much funding has Achilles Therapeutics raised?
Achilles Therapeutics has raised $5.1M across 2 rounds on record. The most recent is a Grant of $4.1M announced in Jul 2022.
When did Achilles Therapeutics last raise funding?
Achilles Therapeutics' most recent funding round on record is a Grant of $4.1M, announced in Jul 2022.
Who founded Achilles Therapeutics?
FundedIQ lists Charles Swanton (Founder) at Achilles Therapeutics.
Who is the CEO of Achilles Therapeutics?
Aseem Ghaghda is listed as CEO at Achilles Therapeutics.
Where is Achilles Therapeutics headquartered?
Achilles Therapeutics is based in London, England, United Kingdom.
How many employees does Achilles Therapeutics have?
Achilles Therapeutics is in the 1-10 employee band.
How does Achilles Therapeutics' funding compare to other Biotechnology startups?
Achilles Therapeutics' latest round of $4.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Achilles Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Achilles Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.